Office of Clinical Research, Asper Clinical Research Institute, St Boniface Hospital Research Centre, 351 Tache Ave., Winnipeg R2H 2A6, MB, Canada Departments of Pharmacology and Therapeutics, Faculty of Medicine, University of Manitoba, 351 Tache Ave., Winnipeg, MB, Canada R2H 2A6;
Office of Clinical Research, Asper Clinical Research Institute, St Boniface Hospital Research Centre, 351 Tache Ave., Winnipeg R2H 2A6, MB, Canada;
Office of Clinical Research, Asper Clinical Research Institute, St Boniface Hospital Research Centre, 351 Tache Ave., Winnipeg R2H 2A6, MB, Canada;
Office of Clinical Research, Asper Clinical Research Institute, St Boniface Hospital Research Centre, 351 Tache Ave., Winnipeg R2H 2A6, MB, Canada;
机译:评估人类研究保护计划的质量,以改善对参与临床试验的人类受试者的保护
机译:PhRMA发布试用指南; 《保护审判对象新指南》;胚胎干细胞试验可能会继续;欧盟临床试验规则受到批评;不保护主题数据的处罚
机译:参与尿酸循环异常的成年和儿科受试者的蛋白质和卡路里摄入,参与甘油丁酸甘油酯的临床试验
机译:保护受试者参与临床试验
机译:社会影响力对非裔美国人参与临床试验的意愿的影响
机译:参与尿酸循环异常的成年和儿科受试者的蛋白质和卡路里摄入参与甘油丁酸甘油酯的临床试验
机译:试验主体保护方面的临床试验和生物等效研究研究